Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489 Greifswald, Germany
Pharmacotherapeutic group: Antihaemorrhagics (vitamins)
ATC code: B02BA01
Konakion MM is a synthetic preparation of vitamin K. The presence of vitamin K (i.e. vitamin K or substances with vitamin K activity) is essential for the formation within the body of prothrombin, factor VII, factor IX and factor X. Lack of vitamin K leads to an increased tendency to haemorrhage. When an antidote to an anticoagulant is necessary it is essential to use vitamin K1 itself, as vitamin K analogues are much less effective.
In the mixed micelles solution, vitamin K1 is solubilised by means of a physiological colloidal system, also found in the human body, consisting of lecithin and bile acid. Owing to the absence of organic solvents, the Konakion mixed micelles solution is well tolerated on intravenous administration.
In blood plasma, 90% of vitamin K1 is bound to lipoproteins.
Following an intramuscular dose of 10mg vitamin K, plasma concentrations of 10–20mcg/l are produced (normal range 0.4–1.2mcg/l).
Systemic availability following intramuscular administration is about 50% and elimination half-life in plasma is approximately 1.5–3 hours.
None applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
